CX3CL1 and rheumatoid arthritis: It has been demonstrated that fractalkine/CX3CL1 plays an important role in the development of RA, suggesting a more aggressive role of this molecule in RA pathogenesis, as well as an association with atherosclerotic damage in these patients.